Metrics cut 1
- D2C expansion placed on hold due to patent issues (previously in test marketing phase)
Event Participants
Executives (3)
Ashutosh Goenka (Chairman & Managing Director), Shubhang Goenka (Whole-Time Director), Vivek Bahety (Chief Financial Officer)
Analysts (5)
Disha (Individual Investor), Hrushikesh Rajesh Shah (Alchemy Capital), Jagdish Sharma (Sincere Syndication), Jignesh (Vedarth Investment), Riya Patel (Individual Investor)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹3,224 lakhs | -3.4% YoY; +10.3% vs Q1 FY25; broadly stable on tariff-disrupted sourcing environment |
| PAT | ₹712 lakhs | +153% YoY (vs ₹281 lakhs); +58% QoQ (vs ₹451 lakhs); supported by other income |
| EPS | ₹6.34 | vs ₹2.51 YoY and ₹4.02 in Q4 FY26 |
| Garment Business Operating Profit | ₹343 lakhs | ~12x improvement vs ₹28.24 lakhs YoY on broadly similar top line; reflects better product mix, pricing discipline, cost control |
| Core EBITDA Margin | ~3.4% | Turned positive vs marginally negative YoY; targeting further normalization toward historical levels |
| Cost of Materials (% of Revenue) | ₹1,472 lakhs (45.7%) | Improved from ~48% last year |
| Total Expenses | ₹3,172 lakhs | -6.9% YoY; ~18.5% QoQ |
| Other Income | ₹711 lakhs | vs ₹402.7 lakhs YoY; includes ₹372.64 lakhs unrealized fair value gain on investments, ₹225.78 lakhs net gain from FX forward reversal/remeasurement, ₹32.91 lakhs realized investment gains — market-linked, may not recur |
| Effective Tax Rate | ~6.6% | Primarily due to unrealized fair value gains attracting minimal current tax |
| Finance Cost | ~₹10 lakhs | Reflects effectively debt-free balance sheet |
| Net Worth | ₹142.65 crores | Book value ~₹127/share, up from ₹130.65 crores at Mar-26 |
| Borrowings | <₹1 crore | Effectively zero leverage |
| Cash + Investments | ~₹80 crores | Substantial liquidity for capacity expansion |
Geographic & Segment Commentary
Premium Woven Bottom Wear / Outerwear (Core Export Segment): Operates exclusively in premium bottom wear and outerwear, avoiding mass-market competition from Bangladesh/Vietnam/Pakistan, competing instead against Turkey, Tunisia, Eastern Europe, Guatemala, and Latin American production bases. Revenue remains ~60% Europe / 40% US currently (shifted from historical 50/50 split as US slowed due to tariffs), with a small base in Australia and Middle East. Customer retention has been resilient — no US customers were lost through the tariff cycle, though volumes and margins were impacted by discounts offered to retain business.
Product Expansion into Women's Wear & Athleisure: Strategy is to supplement, not replace, core premium bottom wear capabilities. Women's wear bottoms are a natural adjacency given product similarities; athleisure capabilities (including man-made fiber sourcing from India and China) are being developed to serve existing customers with more options. D2C entry is on hold due to patent issues encountered during test marketing phase.
Company-Specific & Strategic Commentary
Tariff Mitigation & Geopolitical Diversification: Signed an MoU with a Sri Lankan contract manufacturer to shift country of origin if tariffs on Indian goods become adverse — not yet utilized. Nepal is under evaluation for a wholly-owned plant to diversify manufacturing geography risk; contract manufacturing arrangements are priced/terms-based rather than wholly-owned. Management emphasized these are contingency arrangements, not intended to move existing European/UK business out of India (supported by India-UK and India-EU FTAs).
Capacity Expansion Roadmap: Current capacity of 18 lakh pieces (65% utilization, ~2 lines available in existing facilities) targeted to reach 38 lakh pieces. Phased capex: ~₹20 crores for Phase 1 (operational around early FY28, possibly off by a couple of months) and another ~₹20 crores for Phase 2 by FY30 — total ~₹40-50 crores ballpark. Utilization target: ~70% in FY27, 80% is the planned ceiling before adding capacity, given seasonality.
Premium Positioning & Tariff Reality: Management clarified premium positioning does not insulate the company from tariff impacts — premium product selling prices face proportionally higher tariff burden than mass-market goods — though Meenakshi shared less of the burden than mass-market peers. Actions taken included pricing discounts to partner with US customers and timing shipments to land during favorable tariff windows.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (FY30) | ~₹565 crores (conservative projection) | Management deliberately conservative given EU FTA not operational (expected Q1 CY27), US FTA uncertain; open to surpassing |
| EBITDA Margin (FY28) | ~17% target | Movement toward pre-tariff historical levels; Q1 FY27 core margin ~3.4% is evidence of trajectory; tariff environment remains daily-changing |
| Capacity Utilization (FY27) | ~70% | Up from 65% in Q1; 80% is the planning ceiling before triggering capacity adds |
| Capex | ~₹40-50 crores up to FY30 |
Risks & Constraints
| Risk | Context |
|---|---|
| US Tariff Uncertainty | US policy has been changing on a daily basis for the past two months; currently ~40% of revenue exposed to US. Management mitigated via Sri Lankan contract manufacturing MoU, customer discounts, and shipment timing, but margins remain compressed until trade policy stabilizes |
| Other Income Non-Recurrence | ₹711 lakhs other income includes ₹372.64 lakhs unrealized fair value gains and ₹225.78 lakhs FX forward reversals — management explicitly flagged these are market-linked and may not recur; tax rate of 6.6% is unsustainably low on realized basis |
| Customer Concentration | Top 5 clients contribute ~70% of revenue; top 10 exceed 95%; only 12-20 customers at any time — a key vulnerability if any account is lost or consolidates sourcing |
| D2C Patent Litigation | D2C entry placed on hold due to patent issues; company had invested minimally and test marketing was early stage, limiting downside but also delaying a strategic growth avenue |
| Mass-Market Incursion Risk | Bangladesh, Vietnam, Pakistan compete aggressively on price in mass-market categories; Meenakshi's premium focus avoids direct competition but caps addressable market size |
Q&A Highlights
Premium Bottom Wear Focus & Competitive Positioning (Hrushikesh Rajesh Shah, Alchemy Capital)
- Question: Why the conscious choice to stay in bottom wear with high realizations; can premium manufacturers pass on tariffs more easily?
- Answer: (Ashutosh Goenka) Bottom wear focus stems from pre-2005 quota regime where India had pricing power in that category; (management) premium positioning does not reduce tariff impact — premium products face higher absolute tariff burden. (Shubhang Goenka) Athleisure expands existing capabilities, not a pivot away from core; man-made fiber supply base already exists in India and China.
Capacity Expansion, Capex Phasing & Contract Manufacturing (Hrushikesh Rajesh Shah, Alchemy Capital)
- Question: How much capex for incremental 20 lakh pieces, and why move manufacturing outside India if demand in India is strong?
- Answer: (Vivek Bahety) ~₹20 crores per phase; ₹40-50 crores total up to FY30; Phase 1 operational around FY28, possibly off by a few months. (Shubhang Goenka) Sri Lanka MoU exists solely for contingency on US tariffs — no production has been moved; Nepal is a future plan for geographical diversification. (Ashutosh Goenka) Sri Lankan agreement was to tide over tariff issues only; not yet needed.
Margin Trajectory & Conservative FY30 Guidance (Jagdish Sharma, Sincere Syndication)
- Question: Is the ₹565 crores FY30 revenue / ~17% EBITDA guidance overly conservative given FY25 EBITDA was ₹51 crores?
- Answer: (Shubhang Goenka) The guidance is deliberately conservative — EU FTA not yet operational, US situation contradictory — but achievable; company open to surpassing. (Ashutosh Goenka) FY25 EBITDA included ₹12.5 crores exceptional income from agricultural land sale; core margins of 17% were consistently achieved over the past 3-4 years.
Geographic Mix, Customer Concentration & US Tariff Impact (Riya Patel, Individual Investor)
- Question: What is the geographic revenue split; are US customers staying through tariffs; expansion plans?
- Answer: (Shubhang Goenka) ~60% Europe currently vs ~50/50 historically; US customers all retained despite tariffs, with volumes reduced due to tariff-related and customer overstocking issues; new geographies targeted include Australia, Japan, Canada — China not a target market; top 5 clients ~70% of revenue, top 10 ~95%+.
Domestic Business & Debt-Free Listing (Jignesh, Vedarth Investment)
- Question: Why is the company largely export-only; what was the IPO use of proceeds?
- Answer: (Ashutosh Goenka) No IPO was done — company was listed on Calcutta Stock Exchange (non-functional for 25 years) and migrated via direct listing; domestic margins are less profitable due to quality/compliance setup mismatch. (Shubhang Goenka) FY25 gross revenue ₹191 crores (₹155 crores operational), EBITDA ₹51 crores including ₹12.5 crores exceptional, PAT ₹40 crores.
Geopolitical Hedging & Future Expansion (Disha, Individual Investor)
- Question: What plans cover future US trade policy changes?
- Answer: (Shubhang Goenka) Sri Lankan MoU changes country of origin for customers; further plans include establishing own plants outside India to hedge single-country geopolitical risk; domestic India business remains a limited focus due to margin differentials.
Key Takeaway
Meenakshi India delivered a sharp bottom-line recovery in Q1 FY27 — PAT of ₹712 lakhs (+153% YoY, +58% QoQ) was aided by ₹711 lakhs of other income, but the underlying garment business turned operationally positive at ~3.4% core EBITDA margin (from a loss a year ago) on flat revenue of ₹3,224 lakhs, reflecting improved product mix, pricing discipline, and cost control post the FY26 tariff shock. Management's strategy centers on retaining premium positioning (top-5 clients ~70% of revenue) while executing a phased capacity expansion from 18 to 38 lakh pieces via ~₹40-50 crores capex through FY30, supplemented by contingency manufacturing in Sri Lanka and potential Nepal plants to hedge US policy volatility. Guidance targets ~70% utilization in FY27, ~17% EBITDA margin by FY28, and a conservative ₹565 crores FY30 revenue, with upside from India-UK/EU FTAs. Watch points include non-recurrence of other income, US tariff resolution, and customer concentration — with D2C expansion paused on patent issues.